AU2006228947A1 - Combined-step process for pharmaceutical compositions - Google Patents

Combined-step process for pharmaceutical compositions Download PDF

Info

Publication number
AU2006228947A1
AU2006228947A1 AU2006228947A AU2006228947A AU2006228947A1 AU 2006228947 A1 AU2006228947 A1 AU 2006228947A1 AU 2006228947 A AU2006228947 A AU 2006228947A AU 2006228947 A AU2006228947 A AU 2006228947A AU 2006228947 A1 AU2006228947 A1 AU 2006228947A1
Authority
AU
Australia
Prior art keywords
levetiracetam
pharmaceutical
blend
process according
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006228947A
Other languages
English (en)
Inventor
Lina Al-Bargash
David A. Caron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Pharmaceuticals ULC
Original Assignee
Mylan Pharmaceuticals ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Pharmaceuticals ULC filed Critical Mylan Pharmaceuticals ULC
Publication of AU2006228947A1 publication Critical patent/AU2006228947A1/en
Assigned to GENPHARM ULC reassignment GENPHARM ULC Alteration of Name(s) of Applicant(s) under S113 Assignors: GENPHARM INC.
Assigned to MYLAN PHARMACEUTICALS ULC reassignment MYLAN PHARMACEUTICALS ULC Alteration of Name(s) of Applicant(s) under S113 Assignors: GENPHARM ULC
Priority to AU2012201676A priority Critical patent/AU2012201676B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006228947A 2005-03-30 2006-03-30 Combined-step process for pharmaceutical compositions Abandoned AU2006228947A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012201676A AU2012201676B2 (en) 2005-03-30 2012-03-21 Combined-step process for pharmaceutical compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,505,463 2005-03-30
CA2505463 2005-03-30
PCT/CA2006/000470 WO2006102750A1 (en) 2005-03-30 2006-03-30 Combined-step process for pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012201676A Division AU2012201676B2 (en) 2005-03-30 2012-03-21 Combined-step process for pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AU2006228947A1 true AU2006228947A1 (en) 2006-10-05

Family

ID=37052908

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006228947A Abandoned AU2006228947A1 (en) 2005-03-30 2006-03-30 Combined-step process for pharmaceutical compositions

Country Status (5)

Country Link
US (1) US8216611B2 (enExample)
EP (1) EP1871363A4 (enExample)
JP (1) JP2008534522A (enExample)
AU (1) AU2006228947A1 (enExample)
WO (1) WO2006102750A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
FR2912056B1 (fr) * 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
ATE542525T1 (de) * 2007-10-16 2012-02-15 Pharmathen Sa Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung
JP2010024156A (ja) * 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
ES2865504T3 (es) * 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
EP2179725A1 (en) * 2008-10-23 2010-04-28 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising levetiracetam
EA037187B1 (ru) * 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
HK1216513A1 (zh) 2013-03-15 2016-11-18 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散劑型
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP7264711B2 (ja) * 2019-04-26 2023-04-25 東和薬品株式会社 レベチラセタム含有医薬組成物の製造方法
CN115350178B (zh) * 2022-08-24 2024-04-26 浙江京新药业股份有限公司 一种包含左乙拉西坦的药物组合物
CN119679738B (zh) * 2025-02-27 2025-06-20 福安药业集团宁波天衡制药有限公司 一种巴氯芬片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US5204115A (en) * 1990-12-12 1993-04-20 Suomen Xyrofin Oy Directly compressible xylitol and method
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
JPH11319534A (ja) * 1998-03-18 1999-11-24 Hosokawa Micron Corp 造粒装置
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
YU37602A (sh) 1999-12-01 2005-07-19 Ucb S.A. Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
JP4039782B2 (ja) * 2000-02-15 2008-01-30 小川香料株式会社 粉末酸味料組成物及びその製造方法
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
DE10224170A1 (de) 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
JPWO2004037293A1 (ja) * 2002-10-22 2006-02-23 大日本住友製薬株式会社 安定化組成物
EP1517893A2 (en) 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
CA2525366A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
NZ556630A (en) 2005-01-27 2010-12-24 Alembic Ltd Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
US8431156B2 (en) 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
US20090074854A1 (en) 2009-03-19
US8216611B2 (en) 2012-07-10
EP1871363A4 (en) 2009-01-21
EP1871363A1 (en) 2008-01-02
JP2008534522A (ja) 2008-08-28
WO2006102750A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
JP6092936B2 (ja) 口腔内崩壊錠の製造方法
US8216611B2 (en) Combined-step process for pharmaceutical compositions
JP3563036B2 (ja) セレコキシブ組成物
EP2646003B1 (en) Rapidly dispersing granules, orally disintegrating tablets and methods
US5266331A (en) Controlled release oxycodone compositions
US5656295A (en) Controlled release oxycodone compositions
US20130011543A1 (en) Controlled release oxycodone compositions
AU2003229705A1 (en) High drug load tablet
US20100034876A1 (en) Controlled release oxycodone compositions
JP2013534242A (ja) ナルブフィンを含有する製剤及びそれらの使用
CA2371231A1 (en) Pharmaceutical composition in unit form containing acetylsalicylic acid and clopidogrel hydrogenosulphate
KR20150003726A (ko) 프라수그렐을 함유하는 안정한 즉시방출형 경구 약제학적 조성물
TWI608849B (zh) 可調控釋放度之高載藥量之醫藥組合物及其製備方法
AU2012201676B2 (en) Combined-step process for pharmaceutical compositions
CA2603316C (en) Combined-step process for pharmaceutical compositions
WO2006123213A1 (en) Modified release formulations of gliclazide
HUP0101739A2 (hu) Nyújtott hatású tiagabin készítmények csökkentett mellékhatásokkal
Saraiya Development and Characterization of iron Chelator Sprinkle Granules
EA029709B1 (ru) Твердая пероральная лекарственная форма, содержащая декскетопрофен и трамадол, и способ ее изготовления
WO2005092319A1 (en) Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
Mohan Develoment and Evaluation of Mouth Dissolving Oro Disperssible Pellets of Meclizine Hcl Using Extrution and Spheronization Technique
HK1059210B (en) Controlled release oxycodone compositions
HK1068004B (en) Controlled release oxycodone compositions
MXPA00007471A (es) Composiciones de celecoxib
HK1073255B (en) Controlled release oxycodone compositions

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted